title: Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice.
abstract: Even though hepatitis B virus(HBV) vaccines effectively prevent new cases of HBV infection, with approximately 350 million patients worldwide, chronic HBV infection remains a major health problem because of the associated complications (such as liver cirrhosis and hepatocellular carcinoma) and the limited treatment options. Immunotherapy has the potential to effectively control HBV replication. In this current study, we found that recombinant lentivectors could induce potent HBV surface antigen (HBsAg) specific T cell responses and humoral immune responses. Tagging the HBsAg with immunoglobulin Fc fragment further substantially increased the HBsAg specific immune responses. Remarkably, the HBS-Fc-lv lentivector could effectively break immune tolerance and induce potent HBsAg specific adaptive immune responses in HBsAg transgenic (Tg) mice with low serum level of HBsAg. More importantly, the induction of HBsAg specific immune responses in Tg mice accompanied seroconversion from HBsAg to anti-HBsAg antibody (anti-HBsAb). Our study demonstrated the potential of utilizing lentivector to treat chronic HBV infection following reduction of viral load with antiviral drug therapy.
authors.affiliation: Immunology/Immunotherapy Program, MCG Cancer Center, Georgia Health Science University, Augusta, GA, United States.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Hong
authors.forename: Yibing
authors.initials: Y
authors.lastname: Peng
authors.forename: Michael
authors.initials: M
authors.lastname: Mi
authors.forename: Haiyan
authors.initials: H
authors.lastname: Xiao
authors.forename: David H
authors.initials: DH
authors.lastname: Munn
authors.forename: Gui-Qiang
authors.initials: GQ
authors.lastname: Wang
authors.forename: Yukai
authors.initials: Y
authors.lastname: He
mesh_terms: D000818:Animals; D005822:Genetic Vectors; D006510:Hepatitis B Antibodies / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000235:genetics / Q000276:immunology*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D019694:Hepatitis B, Chronic / Q000517:prevention & control / Q000628:therapy*; D007141:Immunoglobulin Fc Fragments / Q000235:genetics / Q000276:immunology*; D007167:Immunotherapy / Q000379:methods*; D016086:Lentivirus / Q000235:genetics; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology
chemical_list: D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D007141:Immunoglobulin Fc Fragments; D011993:Recombinant Fusion Proteins; D014614:Vaccines, Synthetic